[Angiotensin1-receptor antagonist losartan. Part I. Basic clinical pharmacology].
This is the initial part in a series of papers dealing with various aspects of clinical pharmacology of the first AT(1)-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction. Mechanisms of action, pharmacological effects of losartan and other AT(1)-receptor antagonists, as well as data on pharmacokinetics of losartan, its long term tolerability and safety are reviewed in this communication.
Sidorenko
B A
BA
Preobrazhenskiĭ
D V
DV
Stetsenko
T M
TM
Malysheva
N V
NV
Tsurko
V V
VV
Tarykina
E V
EV
D057911:Angiotensin Receptor Antagonists; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D019808:Losartan / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D010601:Pharmacology, Clinical / Q000379:methods*; D044140:Receptor, Angiotensin, Type 1; D012697:Serine Endopeptidases
D057911:Angiotensin Receptor Antagonists; D000889:Anti-Arrhythmia Agents; D044140:Receptor, Angiotensin, Type 1; D012697:Serine Endopeptidases; C061710:angiotensin II-producing serum enzyme III; D019808:Losartan